BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26382091)

  • 21. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization.
    Valent P; Akin C; Sperr WR; Horny HP; Metcalfe DD
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1227-41. PubMed ID: 14560784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
    Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Pardanani A; Reichard K; Tefferi A
    Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
    Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment.
    Bunimovich O; Grassi M; Baer MR
    Cutis; 2009 Jan; 83(1):29-36. PubMed ID: 19271568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How we diagnose and treat systemic mastocytosis in adults.
    Scherber RM; Borate U
    Br J Haematol; 2018 Jan; 180(1):11-23. PubMed ID: 29048112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mastocytosis, classification, biological diagnosis and therapy].
    Arock M
    Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mastocytosis: pathology, genetics, and current options for therapy.
    Valent P; Akin C; Sperr WR; Mayerhofer M; Födinger M; Fritsche-Polanz R; Sotlar K; Escribano L; Arock M; Horny HP; Metcalfe DD
    Leuk Lymphoma; 2005 Jan; 46(1):35-48. PubMed ID: 15621779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
    Gotlib J; Pardanani A; Akin C; Reiter A; George T; Hermine O; Kluin-Nelemans H; Hartmann K; Sperr WR; Brockow K; Schwartz LB; Orfao A; Deangelo DJ; Arock M; Sotlar K; Horny HP; Metcalfe DD; Escribano L; Verstovsek S; Tefferi A; Valent P
    Blood; 2013 Mar; 121(13):2393-401. PubMed ID: 23325841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis.
    Dasilva-Freire N; Mayado A; Teodosio C; Jara-Acevedo M; Álvarez-Twose I; Matito A; Sánchez-Muñoz L; Caldas C; Henriques A; Muñoz-González JI; García-Montero AC; Sánchez-Gallego JI; Escribano L; Orfao A
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30696068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
    Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
    Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel approaches in the treatment of systemic mastocytosis.
    Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.